Andrew Loblaw on SBRT vs Brachytherapy in Prostate Cancer | ESTRO 2025 скачать в хорошем качестве

Andrew Loblaw on SBRT vs Brachytherapy in Prostate Cancer | ESTRO 2025

At the ESTRO 2025 Congress, Prof. Andrew Loblaw from the University of Toronto presented a comparative analysis of SBRT versus HDR brachytherapy in intermediate-risk prostate cancer. Drawing on data from five prospective trials at Sunnybrook Hospital involving approximately 250 patients, the study found that SBRT was associated with significantly lower recurrence rates at 10 years (10% vs. 38%) compared to HDR monotherapy. While short-term bladder toxicity was higher with brachytherapy, long-term toxicity profiles were similar. Prof. Loblaw also introduced a new international phase III trial comparing SBRT and brachytherapy boost in high-risk patients, aiming to close recruitment within four years. About ESTRO 2025 ESTRO 2025 is the leading global event for radiation oncology professionals, hosted by the European Society for Radiotherapy and Oncology (ESTRO). This congress, held from May 2 to 6, 2025, at the Messe Wien Exhibition & Congress Center in Vienna, Austria, brings together experts from around the world to showcase cutting-edge research, discuss the latest advancements in radiotherapy, and explore future trends in oncology. #ESTRO2025 #ProstateCancer #SBRT #Brachytherapy #RadiationOncology #OncologyResearch #HDRBrachytherapy #CancerTrials #ClinicalOncology SUBSCRIBE to get the latest #oncodaily    / @oncodailytv   Visit the OncoDaily Website : https://oncodaily.com Like OncoDaily on LinkedIn:   / oncodaily   Like OncoDaily on X (Twitter): https://x.com/oncodaily Follow OncoDaily on Instagram:   / oncodailynews   Follow OncoDaily on TikTok:   / oncodaily   Like OncoDaily on Facebook:   / oncodaily   SUBSCRIBE to OncoDaily Newsletter: https://oncodaily.com/submit-newsletter About OncoDaily OncoDaily is a world-leading oncology media platform, which is based in the United States and features the cancer related latest news, insights, and patient stories from around the globe. The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we.”